IN2014DN05869A - - Google Patents
Info
- Publication number
- IN2014DN05869A IN2014DN05869A IN5869DEN2014A IN2014DN05869A IN 2014DN05869 A IN2014DN05869 A IN 2014DN05869A IN 5869DEN2014 A IN5869DEN2014 A IN 5869DEN2014A IN 2014DN05869 A IN2014DN05869 A IN 2014DN05869A
- Authority
- IN
- India
- Prior art keywords
- tautomer
- compounds
- pharmaceutically acceptable
- acceptable salt
- combination
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002062 proliferating effect Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 229960002258 fulvestrant Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960004622 raloxifene Drugs 0.000 abstract 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 abstract 1
- 229960002119 raloxifene hydrochloride Drugs 0.000 abstract 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
- 229960005026 toremifene Drugs 0.000 abstract 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593047P | 2012-01-31 | 2012-01-31 | |
| PCT/US2013/023781 WO2013116293A1 (en) | 2012-01-31 | 2013-01-30 | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05869A true IN2014DN05869A (enExample) | 2015-05-22 |
Family
ID=47679114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5869DEN2014 IN2014DN05869A (enExample) | 2012-01-31 | 2013-01-30 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140378422A1 (enExample) |
| EP (1) | EP2809312A1 (enExample) |
| JP (1) | JP2015505562A (enExample) |
| KR (1) | KR20140117457A (enExample) |
| CN (1) | CN104093402A (enExample) |
| AU (1) | AU2013215251A1 (enExample) |
| BR (1) | BR112014017985A8 (enExample) |
| CA (1) | CA2861377A1 (enExample) |
| IN (1) | IN2014DN05869A (enExample) |
| MX (1) | MX2014009303A (enExample) |
| RU (1) | RU2014135436A (enExample) |
| WO (1) | WO2013116293A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA39741A (fr) * | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes |
| SG11201706143SA (en) | 2015-03-25 | 2017-09-28 | Nat Cancer Ct | Therapeutic agent for bile duct cancer |
| US10118910B2 (en) | 2015-12-09 | 2018-11-06 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
| KR102486722B1 (ko) | 2015-12-17 | 2023-01-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 유방암 치료제 |
| AU2017226389B2 (en) | 2016-03-04 | 2023-02-02 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| IL267795B2 (en) | 2017-01-06 | 2023-02-01 | G1 Therapeutics Inc | Combination therapy for the treatment of cancer |
| US10208011B2 (en) | 2017-02-10 | 2019-02-19 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| US11833119B2 (en) * | 2018-01-10 | 2023-12-05 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| FI3769765T3 (fi) | 2018-03-19 | 2024-05-15 | Taiho Pharmaceutical Co Ltd | Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus |
| KR20200135945A (ko) | 2018-03-28 | 2020-12-04 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간세포 암종 치료제 |
| TWI841598B (zh) * | 2018-09-13 | 2024-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療雌激素受體陽性乳癌之組合療法 |
| EP3888643A4 (en) * | 2018-11-26 | 2022-08-24 | Taiho Pharmaceutical Co., Ltd. | Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy |
| TW202220652A (zh) * | 2020-07-31 | 2022-06-01 | 日商衛材R&D企管股份有限公司 | 乳癌治療劑 |
| AU2022231254A1 (en) * | 2021-03-03 | 2023-09-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition containing cdk4/6 inhibitor and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (enExample) | 1962-09-13 | |||
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| EA006711B1 (ru) | 2000-09-11 | 2006-02-24 | Чирон Корпорейшн | Хинолиноновые производные в качестве ингибиторов тирозинкиназы |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| ITTV20030095A1 (it) | 2003-07-14 | 2005-01-15 | Asolo Spa | Calzatura con sottopiede composito. |
| AU2004288709B2 (en) | 2003-11-07 | 2011-01-06 | Novartis Vaccines And Diagnostics, Inc. | Methods for synthesizing quinolinone compounds |
| SG173317A1 (en) * | 2005-01-27 | 2011-08-29 | Novartis Vaccines & Diagnostic | Treatment of metastasized tumors |
| EP1885187B1 (en) * | 2005-05-13 | 2013-09-25 | Novartis AG | Methods for treating drug resistant cancer |
| NZ563692A (en) | 2005-05-23 | 2011-04-29 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| PL1957074T3 (pl) | 2005-11-29 | 2014-08-29 | Novartis Ag | Preparaty chinolinonów |
| US20080206194A1 (en) * | 2007-02-16 | 2008-08-28 | Glazer Robert I | Method for the treatment of breast cancer |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
-
2013
- 2013-01-30 WO PCT/US2013/023781 patent/WO2013116293A1/en not_active Ceased
- 2013-01-30 AU AU2013215251A patent/AU2013215251A1/en not_active Abandoned
- 2013-01-30 MX MX2014009303A patent/MX2014009303A/es unknown
- 2013-01-30 US US14/375,145 patent/US20140378422A1/en not_active Abandoned
- 2013-01-30 CA CA2861377A patent/CA2861377A1/en not_active Abandoned
- 2013-01-30 EP EP13703295.9A patent/EP2809312A1/en not_active Withdrawn
- 2013-01-30 KR KR1020147021140A patent/KR20140117457A/ko not_active Ceased
- 2013-01-30 BR BR112014017985A patent/BR112014017985A8/pt not_active Application Discontinuation
- 2013-01-30 CN CN201380006947.7A patent/CN104093402A/zh active Pending
- 2013-01-30 IN IN5869DEN2014 patent/IN2014DN05869A/en unknown
- 2013-01-30 JP JP2014555661A patent/JP2015505562A/ja active Pending
- 2013-01-30 RU RU2014135436A patent/RU2014135436A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2861377A1 (en) | 2013-08-08 |
| JP2015505562A (ja) | 2015-02-23 |
| AU2013215251A1 (en) | 2014-08-14 |
| WO2013116293A1 (en) | 2013-08-08 |
| RU2014135436A (ru) | 2016-03-27 |
| US20140378422A1 (en) | 2014-12-25 |
| CN104093402A (zh) | 2014-10-08 |
| BR112014017985A8 (pt) | 2017-07-11 |
| MX2014009303A (es) | 2014-10-14 |
| KR20140117457A (ko) | 2014-10-07 |
| BR112014017985A2 (enExample) | 2017-06-20 |
| EP2809312A1 (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN05869A (enExample) | ||
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MY174339A (en) | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| PH12013501341A1 (en) | Morphinan compounds | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
| EA201101507A1 (ru) | Способы лечения солидных опухолей | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
| CO6630082A2 (es) | Tratamiento de lupus nefritis usando laquinimod | |
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| PH12017501294A1 (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| EA201591175A1 (ru) | Трициклические соединения в качестве ингибиторов cftr |